Evotec Nominates Dr. Hofmann to Board Following Shareholder Agreement

Evotec SE, a life sciences company based in Hamburg, announced the nomination of Dr. Wolfgang Hofmann as an independent member of the Supervisory Board. This decision will be voted on at the upcoming Annual General Meeting (AGM) scheduled for June 11, 2026. The AGM will also address the nomination of Dieter Weinand as Chairman and propose the expansion of the Supervisory Board from six to seven members.

The nomination comes after Evotec's constructive discussions with MAK Capital, a principal shareholder. Through a new cooperation agreement, MAK Capital has agreed to customary voting and collaboration commitments. This engagement underlines Evotec’s dedication to constructive dialogue with shareholders and ongoing transformation efforts.

Prof. Dr. Iris Löw-Friedrich highlighted Dr. Hofmann's industry and governance expertise as pivotal for Evotec’s strategic plans. Meanwhile, Michael A. Kaufman of MAK Capital welcomed the nomination, expressing eagerness for continued collaboration.